John Rim, CEO and president of Samsung Biologics, led this
year’s AGM for the first time since his appointment. For the safety of
shareholders in light of the COVID-19 pandemic, the company took precautionary
measures throughout the meeting in accordance with the Infectious Disease
Control and Prevention Act to ensure the health and safety of all attendees.
Since a limited number of participants were admitted to the onsite meeting,
Samsung Biologics implemented an electronic voting system, and the meeting was
also made available for virtual participation via a live broadcast.
“Despite the global uncertainties with the ongoing pandemic,
Samsung Biologics demonstrated outstanding operational excellence and business
agility even during such extraordinary circumstances,” said John Rim, CEO of
Samsung Biologics in an address to the shareholders. “As we mark the 10th-year
anniversary of Samsung Biologics this year, we set forth our growth plan for
the next decade to become a fully-integrated end-to-end service provider,” Rim
added.
Samsung Biologics continues to rapidly expand its CDMO
business while advancing its biosimilar affiliate and new business models as
part of the company’s multidimensional portfolio expansion strategy.
With Plants 1,2, and 3 showing steady business performance
over the past decade, Plant 4, the newest addition to the company, is expected
to begin manufacturing activities in early 2023, catapulting Samsung Biologics
upon completion to hold the world’s largest manufacturing capacity at a single
site with multi-scale capabilities.
The company also plans to further secure additional
manufacturing facilities both locally and overseas to accommodate the evolving
needs of global clients from multiple locations. In addition to its San
Francisco CDO R&D Center, Samsung Biologics is currently in discussion to
construct Bio Campus 2 in Songdo to further enhance its open innovation as a
new growth engine for the next decade.
0 comments:
Post a Comment